A meta-analysis of randomized clinical trials on the effect of metformin vs. pioglitazone monotherapy on plasma adiponectin levels among patients with diabetes mellitus

The Egyptian Journal of Internal Medicine

Table 1 Characteristics of the included studies

First author and year	Country	N	T2DM	Other medications	Pioglitazone		Metformin		ADP assay
First author and year	Country	N	T2DM	Other medications	Duration	Dose	Duration	Dose	ADP assay
[10]	Turkey	44	Newly diagnosed from outpatient clinics	None	12 weeks	15 mg/day	12 weeks	1 g/day	RIA
[21]	Japan	50	Newly diagnosed from outpatient clinics	Glimepiride (n=6), anti-hypertensive (n=11), low-dose lipid-lowering agent (n=8)	12 weeks	15 mg/day	12 weeks	500 mg/day	ELISA
[22]	Korea	67	T2DM inadequately managed by glimepiride or sulfonylurea	None	24 weeks	15 mg/day	24 weeks	1 g/day	ELISA
[26]	India	30	Newly diagnosed from outpatient clinics	None	12 weeks	15-30 mg/day	12 weeks	1 g/day	ELISA
[27]	Japan	41	Diagnosed from a hospital and no treatment was started	Some patients are treated with sulfonylureas even before the start of the study and was not discontinued.	24 weeks	30 mg/day	24 weeks	750 mg/day	ELISA

N Total number of participants, T2DM Type 2 diabetes mellitus, ADP Adiponectin, RIA radioimmunoassay, ELISA Enzyme-linked immunoassay